The ORR was 19% (8/42, 95% CI 7-31%); confirmed responses include a complete response (CR) and 3 partial responses (PRs) in HER2-mutant NSCLC and 4 PRs in HER2-amplified cholangiocarcinoma, ovarian, endometrial, and salivary gland carcinomas [40]. This evidence concerns the gene ERBB2 and salivary gland carcinoma.